Elevated lipoprotein(a) and fibrinogen serum levels increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 16, Issue 1, 1996, Pages 27-33

  Bartens, Werner ^a,b   Nauck, Matthias ^a   Schollmeyer, Peter ^a   Wanner, Christoph ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Atherosclerosis; Fibrinogen; Lipoprotein(a)

Indexed keywords

FIBRINOGEN; LIPOPROTEIN A;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; IMMUNOBLOTTING; IMMUNORADIOMETRIC ASSAY; LIPOPROTEIN BLOOD LEVEL; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; RISK;

EID: 0030057028     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089601600109     Document Type: Article

References (40)

1. Ponticelli C, Barbi C, Cataluppi A, Donati C, Annoni G, Brancacci D. Lipid abnormalities in maintenance dialysis patients and renal transplant recipients. Kidney Int 1978; 13:572-9.
2. Grundy SM. Management of hyperlipidemia of kidney disease. Kidney Int 1990; 37:847-53.
3. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311:501-5.
4. Meade TM, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park heart study. Lancet 1986; ii:533-7.
5. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. High serum lipoprotein(a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 1992; 38:271-6.
6. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Lipoprotein(a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993; 8:609-13.
7. Utermann G. The mysteries of lipoprotein(a). Science 1989; 246:904-10.
8. Bartens W, Wanner C. Lipoprotein(a): new insights into an atherogenic lipoprotein. Clin Invest 1994; 72:558-67.
9. Scanu AM, Fless GM. Lipoprotein(a) heterogeneity and biological relevance. J Clin Invest 1990;85:1709-15.
10. Zenker G, KoltringerP, Bone G, Niederkorn K, Pfeiffer K, Jurgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986; 17:942-5.
11. Hoff HF, Beck GJ, Skibinski CI, et al. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation 1988; 77:1238-44.
12. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330:132-7.
13. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987; 80:458-65.
14. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 1993; 91:443-7.
15. Karadi I, Romics L, Palos G, et al. Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 1989; 35:2121-3.
16. Wanner C, Rader D, Bartens W, et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993; 119:263-9.
17. Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987; 33:721.
18. Cressmann MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86:475-82.
19. Webb AT, Plant M, Reaveley DA, et al. Lipid and lipoprotein(a) concentrations in renal transplant patients. Nephrol Dial Transplant 1992; 7:636-41.
20. Rose GA, Blackburn H. Cardiovascular survey methods. 2nd ed. Geneva: World Health Organization, 1982:123-43 (World Health Organization monograph series 56).
21. Manual of Laboratory Operation: Lipid Research Clinics Program. DHEW No (NIH) 75-628 Bethesda, National Heart and Lung Institute, 1974:1-74.
22. Wanner C, Hörl WH, Luley CH, Wieland H. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 1991; 39:754-60.
23. Simonet WS, Bucay N, Lauer SJ, Wirak DO, Stevens ME, Weisgraber KH. In the absence of a downstream element, the apolipoprotein E gene is expressed at high levels in kidneys of transgenic mice. J Biol Chem 1990; 265:10809-12.
24. Anwar N, Bhatnagar D, Short CD, et al. Serum lipoprotein(a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993; 8:71-4.
25. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 1995; 10:354-7.
26. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991; 87:2153-61.
27. Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990; 322:1494-9.
28. Werba JP, Safa O, Gianfranceschi G, Michelagnoli S, Sirtori CR, Franceschini G. Plasma triglycerides and lipoprotein(a) inverse relationship in a hyperlipidemic Italian population. Atherosclerosis 1993; 101:203-7.
29. Bartens W, Rader DJ, Talley G, Brewer HB. Decreased plasma levels of lipoprotein(a) in patients with hypertriglyceridemia. Atherosclerosis 1994; 108:149-57.
30. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med 1985; 312:1544-8.
31. Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. J Clin Invest 1989; 83:137-42.
32. Thomas ME, Freestone A, Varghese Z, Persaud JW, Moorhead JF. Lipoprotein(a) in patients with proteinuria. Nephrol Dial Transplant 1992; 7:597-601.
33. Short CD, Durrington PN. Hyperlipidemia and renal disease. Clin Endocrinol Metabol 1990; 4:777-806.
34. Wanner C, Bartens W, Walz G, Nauck M, Schollmeyer P. Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. Nephrol Dial Transplant 1995; 10:75-81.
35. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989; 86:3847-51.
36. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339:303-5.
37. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339:301-3.
38. Miles LA, Plow EF. Lp(a): an interloper into the fibrinolytic system. Thromb Haemost 1990; 63:331-5.
39. Heinrich J, Sandkamp M, Kokott R, Schulte H, Assmann G. Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem 1991; 37:1950-4.
40. Glueck CJ, Glueck HI, Tracy T, Speirs J, McCray C, Stroop D. Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators and d-dimer. Metabolism 1993; 42:236-46.